Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDPK1 | O15530 | 1/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.54 |
| ▸ | PLAU | P00749 | 1/20 | 0.48 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.47 |
| ▸ | SRC | P12931 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.42 |
| ▸ | ABL1 | P00519 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | NOS3 | P29474 | 1/20 | 0.41 |
| ▸ | NOS1 | P29475 | 1/20 | 0.41 |
| ▸ | NOS2 | P35228 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | CASP1 | P29466 | 1/20 | 0.41 |
| ▸ | CASP7 | P55210 | 1/20 | 0.41 |
| ▸ | HBB | P68871 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Isoquinolin-3-Amine SCHEMBL30378027 | 1.00 | PDPK1 (1.00) | PDPK1CYP1A2CYP2A6PLAUFGFR1 | |
| Isoquinolin-3-Amine SCHEMBL29975748 | 1.00 | PDPK1 (1.00) | PDPK1CYP1A2CYP2A6PLAUFGFR1 | |
| Isoquinolin-3-Amine SCHEMBL28187424 | 0.98 | PDPK1 (0.95) | PDPK1CYP1A2CYP2A6PLAUFGFR1 | |
| Isoquinolin-3-Amine SCHEMBL29975463 | 0.82 | PDPK1 (0.67) | PDPK1CYP1A2CYP2A6PLAUFGFR1 | |
| Isoquinolin-3-Amine SCHEMBL28186686 | 0.82 | PDPK1 (0.67) | PDPK1CYP1A2CYP2A6PLAUFGFR1 | |
| SCHEMBL4765233 | 0.78 | PDPK1 (0.64) | PDPK1FGFR1SRCPIK3CBABL1 | |
| SCHEMBL26511313 | 0.78 | MAPT (0.69) | PDPK1PIK3CB | |
| SCHEMBL14244848 | 0.78 | PDPK1 (0.62) | PDPK1FGFR1SRCALDH1A1HSD17B10 | |
| SCHEMBL31259166 | 0.76 | PDPK1 (0.61) | PDPK1PLAUFGFR1SRCPIK3CB | |
| SCHEMBL14627579 | 0.76 | PDPK1 (0.61) | PDPK1PLAUFGFR1SRCPIK3CB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 717 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3826722-B1 | ISOQUINOLINE COMPOUNDS AND USES THEREOF | HOFFMANN LA ROCHE (CH) | 2026-02-18 | — | — | EP | claimed |
| US-12378249-B2 | Isoquinoline compounds and uses thereof | GENENTECH, INC. (US) | 2025-08-05 | — | — | US | claimed |
| CN-114539147-B | Preparation method of 3-halogenated-5, 6,7, 8-tetrahydroisoquinoline | 苏州美诺医药科技有限公司 | 2024-03-22 | — | — | CN | claimed |
| CN-117242074-A | KRAS G12D inhibitors | 百时美施贵宝公司 | 2023-12-15 | — | — | CN | claimed |
| CN-114539147-A | Preparation method of 3-halogenated-5, 6,7, 8-tetrahydroisoquinoline | 苏州美诺医药科技有限公司 | 2022-05-27 | — | — | CN | claimed |
| CN-110669058-A | Tricyclic quinolone carboxylic acid and preparation method thereof | 江西农业大学 | 2020-01-10 | — | — | CN | claimed |
| CN-104597194-B | The high performance liquid chromatography-fluorescence method of 3-chlorine-1,2-propylene glycol | 武汉轻工大学 | 2016-07-06 | — | — | CN | claimed |
| CN-103261167-B | 6 of replacement, 6-condenses nitrogen-containing heterocycle compound and uses thereof | HOFFMAN-LA ROCHE LTD. (CH) | 2016-05-04 | — | — | CN | claimed |
| CN-104597194-A | High performance liquid chromatography-fluorescence detection method for 3-chloro-1,2-propylene glycol | UNIV WUHAN POLYTECHNIC | 2015-05-06 | — | — | CN | claimed |
| EP-1023268-B1 | ISOQUINOLINES AS UROKINASE INHIBITORS | PFIZER LTD (GB) | 2003-05-21 | — | — | EP | claimed |
| US-6248738-B1 | ANTIULCER AGENTS, ANGIOGENESIS INHIBITORS, ANTIMETASTASIS AGENTS, ANTITUMOR AGENTS | PFIZER INC. | 2001-06-19 | — | — | US | claimed |
| CN-1275979-A | Isoquinoline compounds useful as urokinase inhibitors | PFIZER (US) | 2000-12-06 | — | — | CN | claimed |
| EP-1023268-A1 | ISOQUINOLINES AS UROKINASE INHIBITORS | Pfizer Limited (GB) | 2000-08-02 | — | — | EP | claimed |
| WO-1999020608-A1 | ISOQUINOLINES AS UROKINASE INHIBITORS | PFIZER LIMITED (GB) | 1999-04-29 | — | — | WO | claimed |
| EP-4716531-A2 | HETEROCYCLIC COMPOUNDS AS NRAS INHIBITORS | Board of Regents, The University of Texas System (US) | 2026-04-01 | — | — | EP | disclosed |
| US-20260062425-A1 | AZA-TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF | GENENTECH INC (US) | 2026-03-05 | — | — | US | disclosed |
| EP-3826722-B1 | ISOQUINOLINE COMPOUNDS AND USES THEREOF | HOFFMANN LA ROCHE (CH) | 2026-02-18 | — | — | EP | disclosed |
| EP-0047923-B1 | ISOQUINOLINE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | HOECHST AKTIENGESELLSCHAFT (DE) | 1984-05-09 | — | — | EP | disclosed |
| US-4349677-A | 3,4-Dihydro-3,4-isoquinolinedione 4-oxime | MORTON-NORWICH PRODUCTS, INC. (US) | 1982-09-14 | — | — | US | disclosed |
| EP-0047923-A1 | Isoquinoline derivatives, processes for their preparation and pharmaceutical compositions containing them | HOECHST AKTIENGESELLSCHAFT (DE) | 1982-03-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12378249-B2 | Isoquinoline compounds and uses thereof | HIPK1, HPGDS, IP6K1 | PDPK1 35/4885CYP1A2 2773/4885CYP2A6 3700/4885 |
| US-20260062425-A1 | AZA-TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF | KRAS, NRAS, HRAS | PDPK1 2023/4885CYP1A2 1142/4885CYP2A6 702/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.